Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients

C. R. Gregory, I. M. Gourley, G. R. Cain, T. W. Broaddus, Larry D Cowgill, N. H. Willits, J. D. Patz, G. Ishizaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Heterotopic renal allografts following bilateral nephrectomies were placed in 21 healthy mongrel dogs. One group of 11 dogs received cyclosporine (5 mg/kg/24 hr, orally), and 1 group of 10 dogs received cyclosporine and mizoribine (5 mg/kg and 3 mg/kg/24 hr, orally). Body weights, blood cell counts, serum chemistry profiles, serum electrolyte levels, urinalysis with cytology and culture, lymphocyte stimulation assays, immunoglobulin levels, whole blood levels of cyclosporine, and serum levels of mizoribine were followed. At the end of each survival period, necropsy and histopathologic examinations were performed. The mean survival time for the cyclosporine group was 12.8 ± 7 days. The mean survival time for the cyclosporine/mizoribine group was 33.6 ± 16.4 days, significantly longer (P = .0006) than the cyclosporine group. Death in the cyclosporine/mizoribine group was attributed to the combined effects of renal allograft rejection and development of a mizoribine-dependent enteritis. Serum levels of mizoribine were greater in the last half of the survival period due to compromised renal excretion of the drug. There were no complications due to infection, myelosuppression, or hepatotoxicity. Combination cyclosporine/mizoribine immunosuppression enhanced canine renal allograft surival in this study. Monitoring serum concentrations of mizoribine is imperative to determine toxic (enteritis) levels. Availability of an intravenous form of mizoribine would facilitate immunoregulation during periods of variable intestinal absorption or renal excretion.

Original languageEnglish (US)
Pages (from-to)856-859
Number of pages4
JournalTransplantation
Volume45
Issue number5
StatePublished - 1988

Fingerprint

Immunosuppression
Cyclosporine
Allografts
Canidae
Kidney
Serum
Enteritis
Dogs
bredinin
Urinalysis
Blood Cell Count
Poisons
Intestinal Absorption
Lymphocyte Activation
Nephrectomy
Electrolytes
Cell Biology
Immunoglobulins
Body Weight
Infection

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Cite this

Gregory, C. R., Gourley, I. M., Cain, G. R., Broaddus, T. W., Cowgill, L. D., Willits, N. H., ... Ishizaki, G. (1988). Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients. Transplantation, 45(5), 856-859.

Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients. / Gregory, C. R.; Gourley, I. M.; Cain, G. R.; Broaddus, T. W.; Cowgill, Larry D; Willits, N. H.; Patz, J. D.; Ishizaki, G.

In: Transplantation, Vol. 45, No. 5, 1988, p. 856-859.

Research output: Contribution to journalArticle

Gregory, CR, Gourley, IM, Cain, GR, Broaddus, TW, Cowgill, LD, Willits, NH, Patz, JD & Ishizaki, G 1988, 'Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients', Transplantation, vol. 45, no. 5, pp. 856-859.
Gregory CR, Gourley IM, Cain GR, Broaddus TW, Cowgill LD, Willits NH et al. Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients. Transplantation. 1988;45(5):856-859.
Gregory, C. R. ; Gourley, I. M. ; Cain, G. R. ; Broaddus, T. W. ; Cowgill, Larry D ; Willits, N. H. ; Patz, J. D. ; Ishizaki, G. / Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients. In: Transplantation. 1988 ; Vol. 45, No. 5. pp. 856-859.
@article{6e0c431b54504d24861e81f476464d2e,
title = "Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients",
abstract = "Heterotopic renal allografts following bilateral nephrectomies were placed in 21 healthy mongrel dogs. One group of 11 dogs received cyclosporine (5 mg/kg/24 hr, orally), and 1 group of 10 dogs received cyclosporine and mizoribine (5 mg/kg and 3 mg/kg/24 hr, orally). Body weights, blood cell counts, serum chemistry profiles, serum electrolyte levels, urinalysis with cytology and culture, lymphocyte stimulation assays, immunoglobulin levels, whole blood levels of cyclosporine, and serum levels of mizoribine were followed. At the end of each survival period, necropsy and histopathologic examinations were performed. The mean survival time for the cyclosporine group was 12.8 ± 7 days. The mean survival time for the cyclosporine/mizoribine group was 33.6 ± 16.4 days, significantly longer (P = .0006) than the cyclosporine group. Death in the cyclosporine/mizoribine group was attributed to the combined effects of renal allograft rejection and development of a mizoribine-dependent enteritis. Serum levels of mizoribine were greater in the last half of the survival period due to compromised renal excretion of the drug. There were no complications due to infection, myelosuppression, or hepatotoxicity. Combination cyclosporine/mizoribine immunosuppression enhanced canine renal allograft surival in this study. Monitoring serum concentrations of mizoribine is imperative to determine toxic (enteritis) levels. Availability of an intravenous form of mizoribine would facilitate immunoregulation during periods of variable intestinal absorption or renal excretion.",
author = "Gregory, {C. R.} and Gourley, {I. M.} and Cain, {G. R.} and Broaddus, {T. W.} and Cowgill, {Larry D} and Willits, {N. H.} and Patz, {J. D.} and G. Ishizaki",
year = "1988",
language = "English (US)",
volume = "45",
pages = "856--859",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effects of combination cyclosporine/mizoribine immunosuppression on canine renal allograft recipients

AU - Gregory, C. R.

AU - Gourley, I. M.

AU - Cain, G. R.

AU - Broaddus, T. W.

AU - Cowgill, Larry D

AU - Willits, N. H.

AU - Patz, J. D.

AU - Ishizaki, G.

PY - 1988

Y1 - 1988

N2 - Heterotopic renal allografts following bilateral nephrectomies were placed in 21 healthy mongrel dogs. One group of 11 dogs received cyclosporine (5 mg/kg/24 hr, orally), and 1 group of 10 dogs received cyclosporine and mizoribine (5 mg/kg and 3 mg/kg/24 hr, orally). Body weights, blood cell counts, serum chemistry profiles, serum electrolyte levels, urinalysis with cytology and culture, lymphocyte stimulation assays, immunoglobulin levels, whole blood levels of cyclosporine, and serum levels of mizoribine were followed. At the end of each survival period, necropsy and histopathologic examinations were performed. The mean survival time for the cyclosporine group was 12.8 ± 7 days. The mean survival time for the cyclosporine/mizoribine group was 33.6 ± 16.4 days, significantly longer (P = .0006) than the cyclosporine group. Death in the cyclosporine/mizoribine group was attributed to the combined effects of renal allograft rejection and development of a mizoribine-dependent enteritis. Serum levels of mizoribine were greater in the last half of the survival period due to compromised renal excretion of the drug. There were no complications due to infection, myelosuppression, or hepatotoxicity. Combination cyclosporine/mizoribine immunosuppression enhanced canine renal allograft surival in this study. Monitoring serum concentrations of mizoribine is imperative to determine toxic (enteritis) levels. Availability of an intravenous form of mizoribine would facilitate immunoregulation during periods of variable intestinal absorption or renal excretion.

AB - Heterotopic renal allografts following bilateral nephrectomies were placed in 21 healthy mongrel dogs. One group of 11 dogs received cyclosporine (5 mg/kg/24 hr, orally), and 1 group of 10 dogs received cyclosporine and mizoribine (5 mg/kg and 3 mg/kg/24 hr, orally). Body weights, blood cell counts, serum chemistry profiles, serum electrolyte levels, urinalysis with cytology and culture, lymphocyte stimulation assays, immunoglobulin levels, whole blood levels of cyclosporine, and serum levels of mizoribine were followed. At the end of each survival period, necropsy and histopathologic examinations were performed. The mean survival time for the cyclosporine group was 12.8 ± 7 days. The mean survival time for the cyclosporine/mizoribine group was 33.6 ± 16.4 days, significantly longer (P = .0006) than the cyclosporine group. Death in the cyclosporine/mizoribine group was attributed to the combined effects of renal allograft rejection and development of a mizoribine-dependent enteritis. Serum levels of mizoribine were greater in the last half of the survival period due to compromised renal excretion of the drug. There were no complications due to infection, myelosuppression, or hepatotoxicity. Combination cyclosporine/mizoribine immunosuppression enhanced canine renal allograft surival in this study. Monitoring serum concentrations of mizoribine is imperative to determine toxic (enteritis) levels. Availability of an intravenous form of mizoribine would facilitate immunoregulation during periods of variable intestinal absorption or renal excretion.

UR - http://www.scopus.com/inward/record.url?scp=0023727236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023727236&partnerID=8YFLogxK

M3 - Article

C2 - 3285530

AN - SCOPUS:0023727236

VL - 45

SP - 856

EP - 859

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -